ObjectiveTo investigate the application effect of intraoperative lobaplatin intraperitoneal perfusion chemotherapy in patients with primary liver cancer. MethodsA total of 140 patients with primary liver cancer were randomly assigned to study group or control group, with 70 cases in each group. The control group was treated with single hepatectomy, and the study group was treated with lobaplatin intraperitoneal perfusion chemotherapy during hepatectomy. The pre- and postoperative liver function indices in terms of AST, ALT, total bilirubin levels, serum tumor markers with respect to alpha-fetoprotein level, abnormal prothrombin level, and relevant laboratory indices (creatinine level, urea nitrogen level, hemoglobin level, white blood cell counts, platelet counts) were compared between patients of the two groups. The radical resection rate of liver cancer and occurrence of complications were compared between patients of the two groups. Patients were followed up for 6 months, and the recurrence and metastasis of tumor, and survival states of the two groups were statistically analyzed. ResultsThere was no statistically significant difference in the levels of AST, ALT, and total bilirubin between the two groups (P＞0.05). The levels of AST, ALT, and total bilirubin in the two groups exhibited a trend of change with time (P＜0.05). No statistically significant difference in relevant laboratory indices was found between the two groups (P＞0.05), level of hemoglobin, white blood cell counts, and platelet counts exerted a tendency of changes over time (P＜0.05). There were statistically significant differences in serum alpha-fetoprotein and abnormal prothrombin levels between the two groups, therein 7 days, 1 month and 2 months after operation, the levels of serum alpha-fetoprotein and abnormal prothrombin in the study group were lower than those in the control group (P＜0.05). The radical resection rate of liver cancer in the study group was higher than that in the control group (P＜0.05). There was no statistically significant difference in the total incidence rate of complications between the two groups (P＞0.05). After 6-month follow-up of operation, the rates of tumor recurrence and metastasis in the study group were lower than those in the control group (P＜0.05); moreover, there was no statistically significant difference in the death rate between the two groups (P＞0.05). ConclusionEmploying lobaplatin intraperitoneal perfusion chemotherapy during hepatectomy can effectively increase the radical resection rate for patients with primary liver cancer, decrease the levels of serum alpha-fetoprotein and abnormal prothrombin in patients with primary liver cancer, reduce the recurrence and metastasis rates of tumor after operation, exerting a significant clinical efficacy. It does not increase the risk of liver function damage, renal function damage, and bone marrow suppression, with a relatively high safety.

无